Skip to main content

1 Result(s)

within Barbara Sarholz Remove this filter Biomedicine Remove this filter

and

  1. Article

    Open Access

    A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

    This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of peposertib (formerly M3814), a DNA-dependent protein kinase (DNA-PK) i...

    Mark T. J. van Bussel, Ahmad Awada, Maja J. A. de Jonge… in British Journal of Cancer (2021)

    Download PDF (785 KB) View Article